On November 1-2, 2005, the FDA hosted a 2-day public meeting on direct-to-consumer (DTC) promotion of regulated products, including prescription drugs. The FDA is interested in a number of topics relating to DTC.
This survey collected comments from Pharma Marketing Network members, subscribers to Pharma Marketing News, and other pharma marketing professionals regarding the issues that the FDA is interested in.
Just a few of the questions asked:
- How good a job are pharma marketers currently doing to educate consumers about diseases in DTC advertisements in the following media?
- What is the potential role of reminder ads in all types of consumer promotion, such as broadcast, print, and the Internet?
- How good a job are pharma marketers currently doing to educate consumers about communicating risks in DTC advertisements?
- In your opinion, does the use of celebrity endorsements or actors playing doctors in DTC ads mislead consumers about the risk-benefit tradeoffs of prescription drugs?
- Interactive Summary of Results (de-identified, excludes open-ended responses and comments that may identify the respondent). Allows you to use filters to examine results from different subsets of respondents (e.g., pharma company employees vs. non-pharma people, etc.)
- Survey results and selected comments from participants are included in the article “DTC Pros and Cons Presented at FDA Hearing.”